Allogeneic stem cell transplantation (SCT) has been shown to be a curative therapy for some patients with non-Hodgkin's lymphoma (NHL). Total-body irradiation and high-dose cyclophosphamide combinations are the most established conditioning regimens used in this setting. We examined the efficacy and toxicity of cyclophosphamide, BCNU, and VP-16 (CBV) as a suitable chemotherapy-only regimen for NHL patients. In total, 18 patients, median age 42 years, with NHL were treated with CBV followed by allotransplant. Patients had received a median of two prior chemotherapy regimens. Median times to neutrophil and platelet recovery were 19 and 15 days, respectively. Interstitial pneumonitis occurred in one patient. There have been four relapses after a median follow-up of 39 months. Overall, there were four deaths, one because of relapse. The 2-year estimates of relapse-free and overall survival are 56 and 76%, respectively. CBV is a safe and an effective alternative to TBI-containing regimens before allogeneic SCT for NHL.
rates are lower in patients treated with allogeneic SCT, especially for those with chronic GVHD, compared with autotransplant patients; this observation suggests a graftversus-lymphoma effect. 4 Preperative regimens for patients with non-Hodgkin's lymphoma (NHL) undergoing allogeneic SCT frequently include cytoxan plus total-body irradiation (TBI). 5, 6 However, it is unclear whether this regimen has optimal antilymphoma activity; recurrences of 20-60% are reported depending upon histologic subtypes, prior therapies, and tumor chemosensitivity. 1, 5, 7 Furthermore, TBI is associated with interstitial pneumonitis (IP) and patients with prior mediastinal radiation therapy may not be eligible for TBI; the total-radiation dose is one of the most significant risk factors for transplant-related death. 8 Long-term complications of TBI are also concerning and include myelodysplasia, acute leukemia, cataracts, and endocrine insufficiencies. 9, 10 The combination of high-dose cytoxan, carmustine, and etoposide (CBV) has been used extensively as a non-TBIcontaining regimen for patients receiving autologous SCT for lymphoma. [11] [12] [13] In comparison, the experience with CBV for allogeneic transplants is described mostly in series of patients with a history of prior dose-limiting radiotherapy or included among patients treated with various conditioning regimens. [14] [15] [16] Our report is unique in its combination of patients mostly without prior radiation, the exclusion of Hodgkin disease patients, and the carmustine dosing of 450 mg/m 2 rather than the more toxic 600 mg/m 2 .
Patients and methods
All patients and donors gave written informed consent as approved by the Institutional Review Board of University of Massachusetts Medical School. All patients were age 18-55 years with creatinine clearance greater than 70 ml/min, left ventricular ejection fraction greater than 50%, liver transaminases and bilirubin no more than 1.5 times normal, and normal pulmonary function tests. ). No chemotherapy was given on days -2 and -1. Stem cells from a 6/6 HLA-matched sibling were infused on day 0. The first five patients received allogeneic bone marrow and the remaining 13 patients received allogeneic peripheral blood stem cells. One patient received a combination of marrow and peripheral blood-derived stem cells. Post-transplant immunosuppression was achieved using daily cyclosporine beginning day -1 and methotrexate 15 mg/m 2 on day +1 followed by methotrexate 10 mg/m 2 on days +3, +6, and +11. Cyclosporine was tapered between days 100 and 180. All patients received prophylactic antibacterial drugs, acyclovir, bactrim, and low-dose amphotericin according to the policies of the Umass Memorial Health Care Stem Cell Transplant program. Growth factors were not routinely administered. Patients were hospitalized in isolation rooms with laminar air flow and the transplant unit was HEPA filtered.
Treatment regimen

Evaluation of response and engraftment
Tumor staging studies including appropriate imaging were performed 100 days, 12 months, and 24 months after transplant. Bone marrow aspirate and biopsy were performed 100 days, 6 months, and 12 months after transplant. Responses to previous chemotherapy and to the transplant regimen were defined according to standard criteria. 17 Neutrophil count recovery was defined as the first of 3 consecutive days when the absolute neutrophil count exceeded 0.5 Â 10 9 /l blood and platelet count recovery was defined as the day when the platelet count exceeded 20 Â 10 9 /l blood independent of platelet transfusion. Times to cell count recovery were reported from the date of transplant.
Results
Patient characteristics
Between November 1996 and April 2002, 18 patients with NHL were treated with CBV followed by bone marrow or peripheral blood stem cells from HLA-identical sibling donors. Pretransplant characteristics for each patient are shown in Table 1 . There were 14 men and four women with a median age of 42 years (range, 20-50). Disease histology included diffuse large B cell (2), high-grade B cell (4), follicular B cell (4), T cell (3), mantle cell (2), small lymphocytic/CLL (2), and mucosa-associated lymphoid tissue (MALT) (1) lymphomas. Patients had received a median of two chemotherapy regimens prior to transplant conditioning. One patient (no. 7) had previously received an autotransplant and one patient (no. 6) had previously received a T-cell-depleted allogeneic SCT. Three patients had received prior irradiation to the mediastinum (no. 4), total body (no. 6), or neck (no. 15). Five patients had less than a partial response to their last chemotherapy regimen. Among the patients who were transplanted after first-line therapy, one had refractory lymphoma, three had failed to achieve CR, and three were in first CR. First CR patients had high-grade lymphomas and were considered appropriate for allogeneic transplant because of intolerance to repeat cycles of intensive ALL-type regimen (no. 3), bulky disease and first-line therapy with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) only (no. 5), and the presence at diagnosis of three international prognostic index (IPI) risk factors (no. 14). Five patients had bone marrow involved with lymphoma at the time of transplant.
Neutrophil and platelet recovery
All patients had recovery of neutrophil numbers, and the median time to a neutrophil count greater than 0.5 Â 10 9 /l 
Relapse and survival
Five patients have had relapse of lymphoma. Patients 2 and 15 had localized nodal relapse at 35 months and 9 months, respectively, post-transplant. Both received donor lymphocyte infusion (DLI) as treatment for their lymphoma relapse. Both developed GVHD and are without evidence of lymphoma 3 years and 9 months, respectively, after DLI. Patients 9 and 11 had progressive chest adenopathy at 4 months post-transplant. Both patients were treated with local irradiation and achieved resolution of adenopathy. Interestingly, they both subsequently developed chronic GVHD and have had no evidence of lymphoma for the subsequent 26 and 17 months, respectively. Patient 17 had relapsed or persistent MALT lymphoma diagnosed 2 months after transplant and lymphoma was the cause of death. There have been no relapses among high-grade lymphoma patients. No relapses have occurred among patients with GVHD. Surviving patients have been followed for a median of 43 months (range, 7-61 months). The Kaplan-Meier estimates of relapse-free and overall survival after CBV/allogeneic transplantation are shown in Figures 1 and 2 . The 2-year actuarial estimates of relapse-free and overall survival are 56 and 76%, respectively. The median survival for this patient group has not yet been reached.
GVHD and nonrelapse mortality
Clinical outcomes are presented in Tables 1 and 2 . Grade 2 or 3 acute GVHD was diagnosed in four patients; the liver was involved in all four cases and skin was involved in three cases. Extensive chronic GVHD occurred in four patients; all four cases were responsive to immunosuppressive agents and steroids. However, two of these patients developed persistent leukopenia and died of infectious complications.
There was a total of four deaths; three deaths noted above were attributed to complications of therapy. Nonrelapse deaths occurred in patients with multiple prior chemotherapy regimens and long durations of disease. One patient (no. 17) died of relapsed lymphoma. The 100 day and overall nonrelapse mortality were 6 and 17%, respectively.
Pulmonary, hepatic toxicity, and infections
There was one case of regimen-related IP that developed on day 17. One patient was diagnosed with pulmonary fibrosis 6 months after transplant; this patient was also found to have severe nonischemic dilated cardiomyopathy. Three patients with a history of prior radiation therapy did not experience significant pulmonary toxicity. Three patients were diagnosed with mild veno-occlusive disease of the liver; serum bilirubin remained less than 4 g/dl in all cases. One patient developed a mild chronic hepatitis of unknown etiology 7 months after transplant and another developed pancreatitis after 11 months; both of these conditions resolved spontaneously. Sepsis syndrome developed in three patients. Organisms isolated from the blood of these patients were Klebsiella, Enterococcus, and Pseudomonas species. Aspergillus was isolated from three patients with cGVHD; the outcomes were death from aspergillus pneumonia (no. 4) and resolution with itraconazole therapy (no. 11). Patient 7 died of sepsis/multiorgan failure; aspergilloma was found incidentally at autopsy. Neither CMV nor HSV infection was diagnosed in any patient.
Discussion
Our group of patients with relapsed lymphoma treated with CBV and allogeneic SCT experienced high relapse-free and overall survival with a low early mortality rate. Rates of cell count recovery were comparable to rates seen after TBIcontaining regimens. These results suggest that CBV is an acceptable alternative to TBI-containing regimens prior to allogeneic SCT for patients with or without prior radiation therapy.
Our study population was heterogeneous and included patients with follicular lymphomas, aggressive lymphomas, mantle cell lymphoma, and SLL/CLL; this must be considered when comparing our findings with those of other allogeneic SCT trials. Among the four patients with follicular lymphomas, there have been two relapses and one transplant-related death, while among nine aggressive diffuse lymphoma patients who were less heavily pretreated, there has been one relapse and one transplantrelated death.
Owing to the long natural history of the follicular lymphomas, the optimal use of SCT for these patients is poorly defined. It is clear that patients with advanced disease are not cured with conventional chemotherapy and, therefore, transplant approaches are often sought. Heavy pretreatment and the lack of a cure rate with chemotherapy alone often make allogeneic stem cells the preferred source in these cases. Van Besien et al 7 reported 113 patients treated with allogeneic transplantation for low-grade lymphoma; disease-free survival, overall survival, and treatment related mortality were 49, 49, and 40%, respectively, at 3 years. Long-term survival of 25-35% has been reported after allogeneic SCT for salvage therapy for aggressive lymphomas. 1, 5, 18 Published data regarding allogeneic SCT for CLL are limited. Remission rates of 70% and long-term failure-free survival rates of 46-65% have been reported. 19, 20 Both of our SLL/CLL patients remain in CR; one of these patients had failed after a prior T-cell-depleted allotransplant, but has remained in CR for 50 months after the allotransplant performed in this study.
One of our two mantle cell lymphoma patients relapsed after 32 months, but remission was subsequently achieved after DLI. The management of mantle cell lymphoma is particularly challenging because of frequent resistance to chemotherapy; consequently, high relapse rates are often reported following autologous SCT. 21, 22 Recently, a significant benefit from autologous SCT compared to interferon maintenance was reported. 23 Furthermore, among a series of 32 patients treated with allogeneic SCT (including both TBI and non-TBI regimens), the 5-year disease-free survival rate was 41% and no significant difference in outcome has been noted between myeloablative and nonmyeloablative regimens. 24 The patients in our study were offered allogeneic transplantation because of the availability of an identicalmatch sibling donor and young patient age, bone marrow involvement, or a history of heavy pretreatment, including prior high-dose therapy. It is difficult to evaluate the effect of CBV/allogeneic SCT upon overcoming chemo-resistance in our study; most of our patients had disease sensitive to their previous chemotherapy courses. Also, three of our more heavily pretreated patients died of treatment-related complications rather than of relapse. Nevertheless, our results suggest a graft-versus-lymphoma effect; no patient developed a relapse after being diagnosed with GVHD. Furthermore, four of five patients with relapse have had disease remission in the setting of GVHD occurring after the diagnosis of relapse or persistent disease.
In current practice most patients with chemotherapysensitive relapsed aggressive NHL receive autologous SCT. 25, 26 In this setting, long-term relapse-free survivals of 40-50% and treatment-related mortality of 5-10% have been reported. 1, 9, [26] [27] [28] However, relapse of lymphoma remains the primary cause of treatment failure after autologous SCT and myelodysplasia is not uncommon among surviving patients. 29, 30 Although there are no available randomized data to show superiority of an allogeneic approach in NHL, the advantage of tumor-free stem cells and a graft-versus-lymphoma effect make this an attractive alternative for young patients with a history of heavy pretreatment or refractory lymphoma.
3,14,31,32 A graft-versus-lymphoma effect may overcome chemotherapy resistance and allow long-term survival in a minority of refractory lymphoma patients. 33 Unfortunately , improvements in relapse-free survival after allogeneic SCT are generally offset by increased treatment-related mortality. Therefore, strategies for decreasing toxicity while maintaining the engraftment rate and antilymphoma effect could improve outcomes for relapsed or refractory lymphoma patients.
Randomized leukemia trials have shown equivalence between busulfan plus cytoxan and cytoxan plus TBI. 34, 35 However, in the absence of randomized lymphoma trials, the comparative effect of TBI vs non-TBI-containing regimens is unknown. Uncontrolled studies may be biased against chemotherapy-only regimens because they are offered to patients with the most resistant disease requiring local radiotherapy. 33 Nonrandomized comparisons have generally shown equivalent relapse-free survival and overall survival between chemotherapy-only and chemotherapy-TBI regimens 1, 36 Williams et al 37 reported a trend toward shorter survival among TBI-treated autotransplant patients. An observational study of 113 low-grade lymphoma patients receiving allogeneic SCT showed superiority of TBI regimens; however, the majority of chemotherapy-only patients received busulfan plus cytoxan; 7 this combination may not have optimal antilymphoma activity and the relapse rate is high after busulfan/cytoxan. 38 TBI is associated with significant pulmonary toxicity, especially after previous mediastinal irradiation, and it should not be used after a history of radiation toxicity or dose-limiting therapy to the chest, liver, or CNS.
Non-TBI-containing preparative regimens such as CBV have been used most commonly prior to autologous SCT for Hodgkins and NHL. 14, 39, 40 Although IP remains an important cause of toxic death, toxicity of CBV has been reduced by using a BCNU dose of 300-450 mg/m 2 rather than 600 mg/m 2 , and the substitution of lomustine for BCNU may also reduce pulmonary toxicity. 9, 39, 41 An early study of CBV for allotransplantation reported no significant organ toxicity among 29 acute leukemia patients. 16 In the recently reported LNH87-2 protocol for poor-risk aggressive NHL, there were no toxic deaths and no cases of late myelodysplasia among 125 autologous SCT patients receiving CBV with a BCNU dose of 300 mg/m. 2, 42 Treatment-related toxicity was relatively low among our study patients. Pulmonary toxicity occurred in two patients (11%) with one death (6%) because of IP. This compares favorably with the 10-20% rates of death from pulmonary causes reported in other series of lymphoma patients receiving allogeneic transplantation. 5, 7, 14 Of note, two of our patients who had received prior TBI or chest RT did not experience pulmonary toxicity. VOD was infrequent in our study and the cases were not life-threatening. The 6% observed 100-day mortality of our study compares favorably to other reports of allogeneic SCT for lymphoma [3] [4] [5] . Nonrelapse mortality was comparable to the rates seen after nonmyeloablative transplant. 43 These acceptable rates of toxicity among our patients could relate to the absence of TBI conditioning, the dose of BCNU, and/or the low percentage of patients with a history of radiation therapy.
Times to cell count recovery and the total duration of neutropenia and thrombocytopenia were comparable to other reports of allotransplant for lymphoma. 15, 33, 44 This indicates that CBV is sufficiently immunosuppressive to allow engraftment of donor hematopoietic cells. Other investigators have shown that CBV permits allogeneic stem cell engraftment in lymphoma patients with prior doselimiting radiation therapy. In one series of 56 patients treated with CBV containing BCNU 600/m 2 , neutrophil and platelet recovery occurred at median times of 20 and 22 days, respectively. However, 11% of patients died without neutrophil recovery and 33% died without platelet recovery.
14 Effective engraftment has been reported after CBV/allogeneic SCT for Hodgkin's lymphoma; these patients may be more immunosuppressed and less likely to exhibit host-versus-graft resistance than patients with NHL. 15 Additionally, Zander et al 16 confirmed the presence of donor hematopoiesis in all but one of 29 leukemia patients treated with CBV.
In summary, high-dose CBV chemotherapy permits engraftment of HLA-matched sibling donor hematopoietic stem cells. Treatment of NHL patients with this regimen is associated with an excellent relapse-free survival and low transplant-related mortality. Our study results add to the available data supporting the use of CBV as an alternative to TBI-containing regimens in lymphoma. NHL patients who are candidates for allogeneic SCT, but who have an increased risk for TBI-related toxicity may benefit from a chemotherapy-only conditioning regimen. A randomized trial comparing CBV to Cytoxan/TBI may be warranted.
